SeaBeLife Biotech est une entreprise de biotechnologie, créée en Mars 2019, qui valorise les travaux de recherche menés au CNRS, à l'INSERM et dans les universités de Lyon et de Poitiers.
Location: France
Employees: 11-50
Phone: +33 2 98 29 23 48
Total raised: $5.11M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 22.03.2022 | Business A... | business-a... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 01.10.2025 | Seed | $2.34M | Femmes Bus... |
| 27.09.2023 | Seed | $1.27M | - |
| 15.03.2022 | - | $1.5M | - |
Persons 4
| Date | First Name | Last Name | Title | Location | |||
| - | Morgane | Rousselot | - | linkedin.c... | - | m*********... | - |
| - | Pierre | Roudaut | Investisse... | linkedin.c... | - | c*****t@se... | - |
| - | Claire | Delehouzé | CTO | linkedin.c... | - | c*********... | - |
| - | Romain | LUCAS | Head of Ch... | linkedin.c... | - | r*********... | - |
Mentions in press and media 12
| Date | Title | Description |
| 06.10.2025 | NanoPhoria closes €83.5 million Series A for its heart failure candidate – one of Italy’s largest 2025 BioTech rounds | Milan-based NanoPhoria Bioscience today announced the successful first close of its €83.5 million Series A financing round – the largest ever Series A round in Italian BioTech history – for its lung-to-heart drug delivery platform. The roun... |
| 03.10.2025 | French Biotech SeaBeLife Secures €2 Million to Tackle Dry AMD and Severe Acute Hepatitis | French biotech SeaBeLife secures €2 million in a pre-Series A funding round. This capital accelerates groundbreaking drug development for severe acute hepatitis and dry age-related macular degeneration (AMD). The company pioneers a unique, ... |
| 01.10.2025 | French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis | Roscoff-based SeaBeLife, a BioTech company developing innovative drug candidates intended to block cellular necrosis, today announces a pre-Series A funding round worth €2 million. The financing was led by historical investor iXLife, alongs... |
| 01.10.2025 | French biotech SeaBeLife raises €2M to treat liver and eye diseases | French biotech company SeaBeLife has secured €2 million in a pre-Series A funding round to advance its drug development pipeline, with clinical trials expected to begin in 2026. The financing, led by existing investor iXLife and joined by n... |
| 22.04.2024 | Biotech SeaBeLife awarded €1.5M to combat visual degeneration | SeaBeLife, a biotech company developing drugs intended to block cellular necrosis, has been awarded over €1.5M for its SeaBeEYE project at the i-Nov 2024 innovation competition. Funded by the French government’s France 2030 investment plan ... |
| 27.09.2023 | SeaBeLife secures €1.2M to develop drug candidates intended to block cell necrosis | French biotech firm SeaBeLife has raised €1.2 million in additional seed funding to fund the further development of its drug candidates for acute liver disease and eye disorders as well as allow it to expand its team. The company intends to... |
| 26.09.2023 | SeaBeLife Raises €1.2M in Seed Funding | SeaBeLife, a Roscoff, France-based biotech company developing drug candidates intended to block cell necrosis, raised €1.2M in additional Seed funding. The round, which brough the total amount to €1.6M, was led by XLife fund and business an... |
| 15.03.2022 | SeaBeLife Raises €1.37M Financing from Bpifrance Funds | SeaBeLife, a Brittany, France-based biotech company, raised €1.37M in financing from Bpifrance Funds. The financing will be paid out in two installments via the French government’s ‘Future Investments Program’: €959k ($1.04M) in the form of... |
| 14.03.2022 | Brittany-based biotech startup SeaBeLife picks up €1.4 million | Founded in 2019, SeaBeLife is a biotech startup developing drug candidates to block cell necrosis. Today, it’s announced a funding boost of almost €1.4 million financing from Bpifrance. SeaBeLife specialises in the development of drug candi... |
| 14.03.2022 | Stopping destructive cell death in its tracks, SeaBeLife secures €1.37 million | Brittany-based biotech startup SeaBeLife has been awarded €1.37 million from Bpifrance, as part of the French government’s deeptech plan initiative. Niche to say the least, but if successful, SeaBeLife’s approach to blocking the death of ce... |
Show more